I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on February 10, 2005.

AMENDMENT UNDER 37 CFR §1.111

Examining Group 1654
Patent Application

Docket No. UF-266X Serial No. 10/067,495

RECEIVED
CENTRAL FAX CENTER

FEB 1 0 2005

Jenna M. Morrison, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner

Jennifer I. Harle

Art Unit

1654

Applicants

Benjamin A. Horenstein, Hongbin Sun

Serial No.

10/067,495

Filed

February 4, 2002

Conf. No.

7011

For

Inhibitors of Glycosyltransferase Enzymes

MAIL STOP AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313

AMENDMENT UNDER 37 CFR §1.111

Sir:

In response to the Office Action dated January 10, 2005, please amend the above-identified patent application as follows:

FACSIMILE COVER SHEET

SALIWANCHIK, LLOYD & SALIWANCHIK

A Professional Association P.O. Box 142950 Gainesville, FL 32614-2950

RECEIVED CENTRAL FAX CENTER

Telephone (352) 375-8100 Facsimile (352) 372-5800

TO:

Examiner Jennifer I. Harle

FROM: Jenna M. Morrison.

(Reg. No. 55,468)

COMPANY: U.S. Patent & Trademark Office

DATE:

February 10, 2005

FAX NO.:

(703) 872-9306

NO. OF PAGES:

17

(INCLUDING COVER SHEET)

SUBJECT/MESSAGE:

U.S. Patent Application Docket No. UF-266X

INHIBITORS OF GLYCOSYLTRANSFERASE ENZYMES

(Horenstein, Sun)

Serial No. 10/067,495; Filed February 4, 2002

ATTACHMENTS:

Amendment Transmittal Letter (1 page)

Amendment Under 37 CFR § 1.111 (15 pages)

THIS IS AN OFFICIAL DOCUMENT. PLEASE DELIVER IMMEDIATELY. Thank you.

The information contained in this facsimile message is intended only for the personal and confidential use of the designated recipients named above. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message by mail. Thank

If you do not receive all pages or if any transmission is not legible, call the sender at (352) 375-8100.

AMENDMENT TRANSMITTAL LETTER			ATTORNEY'S DOCKET NO. UF-266X
SERIAL NO. 10/067,495	FILING DATE February 4, 2002	EXAMINER Jennifer I. Harle	GROUP ART UNIT 1654
INVENTION Inhibitors of Glyco	syltransferase Enzymes		

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS:

Transmitted herewith is an amendment in the above-identified application.

- Small entity status of this application under 37 CFR 1.27 has been established by a verified statement previously submitted.
- Applicant claims small entity status. \otimes
- A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.

(3)

No additional fee is required.

(1)

The fee has been calculated as shown below: 図

CLAIMS EMAINING AFTER MENDMENT	HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA

(2)

	AFTER AMENDMENT		PAID FOR	LXIKA
TOTAL	59	MINUS	56	3
INDEP.	3	MINUS	3	0
FIRST PRE	SENTATION OF MU	ם באו בי וסודה	ENIDENIT CI AINA	

SMAI	J. E	NTT	TV
DIATAL TY	لاسک سال	TATY	A I

RATE	ADDIT. FEE
\$ 25	\$75.00
\$100	\$ 0.00
\$180	\$ 0.00
Total addit. fee	\$75.00

<u>OR</u>

<u>OR</u>

OTHER THAN A SMALL ENTITY

RATE	ADDIT. FEE
S 50	\$0.00
\$200	\$0.00
\$360	\$0.00
Total addit. fee	\$0.00

The Highest No. Previously Paid For (Total or Indep.) is the highest number found in the appropriate box in Col. 1.

宮	Please charge my Deposit Account No	. 19-0065 in the amount of \$ 75.00
---	-------------------------------------	-------------------------------------

- A check in the amount of \$_____ to cover the filing fee is enclosed.
- The Commissioner is hereby authorized to charge payment of the following fees associated with \boxtimes this communication or credit any overpayment to Deposit Account No. 19-0065. Two additional copies of this paper are enclosed.
 - Any additional filing fees required under 37 CFR 1.16.
 - Any patent application processing fees under 37 CFR 1.17. Ø

Jenna M. Morrison

February 10, 2005

(signature)
Registration No. 55,468

J:\UF\266X\Amend-Resp\Amendment.Transmittal,Letter-NEW.doc/DNB/ssa

^{*} If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

^{**} If the Highest No. Previously Paid For IN THIS SPACE is less than 20, enter "20."

^{***} If the Highest No. Previously Paid For IN THIS SPACE is less than 3, enter "3."